Fig. 5 | Scientific Reports

Fig. 5

From: Cirsiliol alleviates experimental inflammatory bowel disease via restoration of intestinal barrier integrity and inhibition of NF-κB and MAPK pathways

Fig. 5

Anti-inflammatory efficacy of cirsiliol in vivo. (A) TNF-α, IL-6, IL-1β expression levels via ELISA analysis. (B) MCP-1 and iNOS expression levels via ELISA analysis. Cir-Low: 10 mg/kg of cirsiliol; Cir-High: 30 mg/kg of cirsiliol. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 indicate statistically significant differences compared to Ethanol 50% group.

Back to article page